<- Go Home
PharmaResearch Co., Ltd.
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults through the physical restoration; Rejuran HB plus which is used for temporary improvement of adult's crow's feet wrinkles; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; and Rejuvenex cream, which treats the wound through rapid tissue regeneration. It also provides REJURAN, a medical device for face (especially eye, perioral area), neck, Décolleté, hands, etc; CLEVIEL prime plus and contour plus with lidocaine medical devices; D+CELL 350 TRA I; and REJURAN moisturizer for daily skin protection, as well as REJUVENEX SCULPT V; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. In addition, the company offers D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; REJURAN FORTE; and CONJURAN medical devices. Further, it offers functional foods; and engages in the development of software and consulting businesses. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Gangneung-si, South Korea.
Market Cap
N/A
Volume
116.3K
Cash and Equivalents
KRW 175.7B
EBITDA
KRW 228.1B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
KRW 411.2B
Profit Margin
76.68%
52 Week High
KRW 713.0K
52 Week Low
KRW 278.5K
Dividend
N/A
Price / Book Value
4.60
Price / Earnings
N/A
Price / Tangible Book Value
N/A
Enterprise Value
KRW 2.8T
Enterprise Value / EBITDA
N/A
Operating Income
KRW 212.3B
Return on Equity
25.99%
Return on Assets
13.97
Cash and Short Term Investments
KRW 614.4B
Debt
KRW 213.0B
Equity
KRW 724.6B
Revenue
KRW 536.3B
Unlevered FCF
KRW 115.8B
Sector
Biotechnology
Category
N/A